Antibodies derived rom anti ED-B L19 and targeting tumor vasculature

Details for Australian Patent Application No. 2003219370 (hide)

Owner Philogen S.p.A. Bayer Schering Pharma Aktiengesellschaft

Inventors Borsi, Laura; Friebe, Matthias; Zardi, Luciano; Hilger, Christoph-Stephan; Balza, Enrica; Carnemolla, Barbara; Castellani, Patrizia

Agent Davies Collison Cave

Pub. Number AU-B-2003219370

PCT Number PCT/IB03/01458

PCT Pub. Number WO2003/076469

Priority 60/363,045 11.03.02 US

Filing date 11 March 2003

Wipo publication date 22 September 2003

Acceptance publication date 15 January 2009

International Classifications

C12N 15/09 (2006.01) Mutation or genetic engineering - Recombinant DNA-technology

A61K 38/00 (2006.01) Medicinal preparations containing peptides

A61K 39/395 (2006.01) Medicinal preparations containing antigens or antibodies - Antibodies

A61K 51/10 (2006.01) Preparations containing radioactive substances for use in therapy or testing

A61P 9/00 (2006.01) Drugs for disorders of the cardiovascular system

A61P 35/00 (2006.01) Antineoplastic agents

A61P 43/00 (2006.01) Drugs for specific purposes, not provided for in groups

C07K 16/18 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies - against material from animals or humans

C07K 16/44 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies - against material not provided for elsewhere

C07K 19/00 (2006.01) Hybrid peptides

C12N 1/15 (2006.01) Micro-organisms, e.g. protozoa - modified by introduction of foreign genetic material

C12N 1/19 (2006.01) Micro-organisms, e.g. protozoa - modified by introduction of foreign genetic material

C12N 1/21 (2006.01) Micro-organisms, e.g. protozoa - modified by introduction of foreign genetic material

C12N 5/10 (2006.01) Undifferentiated human, animal or plant cells, e.g. cell lines - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells

C12N 15/13 (2006.01) Mutation or genetic engineering - Immunoglobulins

C12P 21/00 (2006.01) Preparation of peptides or proteins

Event Publications

31 July 2003 Complete Application Filed

  Priority application(s): 60/363,045 11.03.02 US

30 October 2003 Application Open to Public Inspection

  Published as AU-B-2003219370

15 January 2009 Alteration of Name

  The name of the applicant has been altered to Philogen S.p.A.; Bayer Schering Pharma Aktiengesellschaft

15 January 2009 Application Accepted

  Published as AU-B-2003219370

14 May 2009 Standard Patent Sealed

8 March 2012 Assignment Registered

  Bayer Schering Pharma Aktiengesellschaft; Philogen S.p.A. The patent has been assigned to Philogen S.p.A

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2003219371-STOCHASTIC DC CONTROL

2003219369-Orthogonalized spatial multiplexing for wireless communication